# Adult-Onset Diabetes and Liver Fibrosis as Diagnostic Clues to Alström Syndrome: A Case Report

**Authors:** Favour Balogun, Shreya Honarius, Megan Li Yuen Yeoh, Mahmoud Abouibrahim, Mostafa Sayed, Joanne Randall

PMC · DOI: 10.7759/cureus.102959 · 2026-02-04

## TL;DR

A 45-year-old man was diagnosed with Alström syndrome after showing late signs like diabetes and liver fibrosis, despite having early visual and hearing loss.

## Contribution

This case highlights atypical diagnostic clues for Alström syndrome in adulthood, aiding in the recognition of a rare genetic disorder.

## Key findings

- Adult-onset diabetes and liver fibrosis can be late indicators of Alström syndrome.
- Early visual and hearing loss combined with later metabolic and hepatic issues suggest ALMS.
- Genetic testing confirmed the diagnosis after years of undiagnosed symptoms.

## Abstract

Alström syndrome (ALMS) is a rare, autosomal recessive condition characterized by progressive multiorgan dysfunction, including vision and hearing loss, obesity, type 2 diabetes mellitus (T2DM), and hepatic and renal impairment. The significant clinical variability and complexity of ALMS often lead to diagnostic delays, with symptoms frequently progressing over many years. This case details a 45-year-old man with a history of early-onset visual impairment and hearing loss (diagnosed at the age of 9-10 years) who subsequently had a late diagnosis of ALMS following the discovery of significant hepatic fibrosis of unknown cause and recent diagnosis of diabetes mellitus without diabetes related antibodies. Given the constellation of symptoms, genetic testing was requested, which ultimately confirmed the diagnosis of ALMS, highlighting how atypical features and delayed recognition can underscore a rare condition with advanced, yet previously unappreciated, organ pathology.

## Linked entities

- **Diseases:** Alström syndrome (MONDO:0008763), type 2 diabetes mellitus (MONDO:0005148)

## Full-text entities

- **Genes:** NUP210 (nucleoporin 210) [NCBI Gene 23225] {aka GP210, POM210}, GGTLC5P (gamma-glutamyltransferase light chain 5 pseudogene) [NCBI Gene 653590] {aka GGT}, ALMS1 (ALMS1 centrosome and basal body associated protein) [NCBI Gene 7840] {aka ALSS}, SLC30A8 (solute carrier family 30 member 8) [NCBI Gene 169026] {aka ZNT8, ZnT-8}, INS (insulin) [NCBI Gene 3630] {aka IDDM, IDDM1, IDDM2, ILPR, IRDN, MODY10}, GPT (glutamic--pyruvic transaminase) [NCBI Gene 2875] {aka AAT1, ALT, ALT1, GPT1, SGPT}, INSM2 (INSM transcriptional repressor 2) [NCBI Gene 84684] {aka IA-6, IA6, mlt1}, SLC17A5 (solute carrier family 17 member 5) [NCBI Gene 26503] {aka AST, ISSD, NSD, SD, SIALIN, SIASD}, TRIM21 (tripartite motif containing 21) [NCBI Gene 6737] {aka RNF81, RO52, Ro/SSA, SSA, SSA1, TRIM21/Ro52}, SLA (Src like adaptor) [NCBI Gene 6503] {aka SLA1, SLAP}, PML (PML nuclear body scaffold) [NCBI Gene 5371] {aka MYL, PP8675, RNF71, TRIM19}, GAD1 (glutamate decarboxylase 1) [NCBI Gene 2571] {aka CPSQ1, DEE89, GAD, GAD-67, SCP}, PTPRN (protein tyrosine phosphatase receptor type N) [NCBI Gene 5798] {aka IA-2, IA-2/PTP, IA2, ICA512, R-PTP-N}, SP100 (SP100 nuclear body protein) [NCBI Gene 6672] {aka lysp100b}, GGT1 (gamma-glutamyltransferase 1) [NCBI Gene 2678] {aka CD224, D22S672, D22S732, GGT, GGT 1, GGTD}
- **Diseases:** visual impairment (MESH:D014786), hepatic and renal dysfunctions (MESH:D008107), autosomal recessive condition (MESH:D020763), inflammatory (MESH:D007249), fatty (MESH:D008067), ALMS (MESH:D056769), hyperglycemia (MESH:D006943), cirrhosis (MESH:D005355), Liver Fibrosis (MESH:D008103), cone-rod dystrophy (MESH:D000071700), NAFLD (MESH:D065626), Renal failure (MESH:D051437), sensory impairment (MESH:D012678), Diabetes (MESH:D003920), overweight (MESH:D050177), retinopathy (MESH:D058437), steatosis (MESH:D005234), obesity (MESH:D009765), multiorgan dysfunction (MESH:D009102), blindness (MESH:D001766), ciliopathies (MESH:D000072661), metabolic dysfunction (MESH:D008659), Sensorineural hearing loss (MESH:D006319), autosomal recessive genetic disorder (MESH:D030342), acanthosis nigricans (MESH:D000052), hearing loss (MESH:D034381), metabolic dysregulation (MESH:D021081), death (MESH:D003643), diabetic complications (MESH:D048909), hyperinsulinemia (MESH:D006946), hypokinesia (MESH:D018476), Viral Hepatitis (MESH:D014777), visual and hearing impairment (MESH:D006311), insulin resistance (MESH:D007333), Renal involvement (MESH:C565423), dilated cardiomyopathy (MESH:D002311), cardiovascular disease (MESH:D002318), retinal dystrophy (MESH:D058499), vision and hearing loss (MESH:D054062), hepatic disease (MESH:D056486), Hepatic, renal, and cardiac complications (MESH:D006331), retinal disease (MESH:D012164), insulin dependence (MESH:D003922), Adult-Onset Diabetes (MESH:D003924), nephropathy (MESH:D007674), heart failure (MESH:D006333), BBS (MESH:D020788)
- **Chemicals:** PBI-4050 (MESH:C000655033), glucose (MESH:D005947), Creatinine (MESH:D003404)
- **Species:** Hepatovirus A (no rank) [taxon 12092], Homo sapiens (human, species) [taxon 9606]
- **Mutations:** c.2938dupA, A4C

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12965190/full.md

---
Source: https://tomesphere.com/paper/PMC12965190